Browsing by Author "Yavas, G."
Now showing 1 - 13 of 13
- Results Per Page
- Sort Options
Item 1.5-Tesla Magnetic Resonance-Guided Adaptive Stereotactic Body Radiotherapy for Liver Malignancies(2023) Onal, C.; Yavas, G.; Yavas, C.; Arslan, G.; Efe, E.; Haberal, M.Item Dose Escalation with Integrated Boost Using High-Field MR-LINAC in Prostate Cancer Patients(2023) Onal, C.; Arslan, G.; Yavas, C.; Efe, E.; Yavas, G.Item The Effect of the Time Interval between Temozolomide and Radiotherapy in Adjuvant High-Grade Glioma Treatment(2022) Oymak, E.; Demircan, V.; Senyurek, S.; Yavas, G.; Guler, O. C.; Bolukbasi, Y.; Erpolat, P.; Onal, C.Item The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma(2021) Onal, C.; Sari, S. Yuce; Yavas, G.; Guler, O. C.; Yigit, E.; Oymak, E.; Gultekin, M.; Yildiz, F.Item Novel Treatment Approach for Inoperable Bladder Cancer: 1.5 Tesla MRI-Guided Online Adaptive SBRT(2023) Yavas, G.; Yavas, C.; Efe, E.; Arslan, G.; Onal, C.Item The Outcomes of Definitive Radiotherapy in Patients with Prostate Cancer Using Simultaneous Integrated Boost Technique(2022) Onal, C.; Guler, O. C.; Erbay, G.; Oymak, E.; Yavas, C.; Yavas, G.; 0000-0002-1706-8680; AAK-5370-2021Item SBRT and Tyrosine Kinase Inhibitors in Patients with Oligometastatic Renal Cell Carcinoma(2023) Onal, C.; Oymak, E.; Guler, O. C.; Tilki, B.; Yavas, G.; Hurmuz, P.; Yavas, C.; Ozyigit, G.Item Treatment Outcomes of 1.5 T MR-Guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancer(2023) Yavas, G.; Yavas, C.; Arslan, G.; Efe, E.; Onal, C.Item The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008(2022) Guler, O. C.; Hurmuz, P.; Atalar, B.; Guney, Y. Yukselen; Saglam, E. K.; Akyurek, S.; Bolukbasi, Y.; Gural, Z.; Tugrul, F.; Korcum, A. F.; Sen, C. A.; Yildirim, B. Akkus; Oksuz, D. C.; Celik, O. Karakoyun; Kurt, M.; Guzeloz, Z.; Yavas, G.; Ozyigit, G.; Aksu, M. G.; Onal, C.; 0000-0001-9724-253X; 0000-0003-1043-8105; GNH-4101-2022; G-9920-2016Item The Treatment Outcomes of Patients with Cervical Esophageal Carcinoma Undergoing Definitive Chemoradiotherapy: A Multi-Institutional Analysis TROD 01-005(2022) Guler, O. C.; Oymak, E.; Yazici, G.; Akagunduz, O. Ozkaya; Cetinayak, O; Erpolat, P.; Aksoy, A.; Duzova, M.; Yildirim, B. Akkus; Kurt, M.; Canyilmaz, E.; Akyurek, S.; Atalar, B.; Yavas, G.; Oksuz, D. C.; Saglam, E. K.; Celik, O. Karakoyun; Cengiz, M.; Onal, C.; 0000-0002-5399-5430; AAA-1349-2022Item Uterine Perforation During Image-Guided Adaptive Brachytherapy in Cervical Cancer Patients(2021) Yavas, G.; Yavas, C.; Inan, G.; Duzova, M.; Gul, O.V.; Basaran, H.Item The Utility of Dissected Lymph Node Number and Lymph Node Metastasis Ratio In Stage IIIC Endometrium Adenocarcinoma: A Multicentric Analysis(2018) Yildirim, B. Akkus; Onal, C.; Sari, S. Yuce; Yavas, G.; Gultekin, M.; Guler, O. C.; Yildiz, F.; Akyurek, S.; https://orcid.org/0000-0001-6661-4185; V-5717-2017; HOC-5611-2023Item The Utility of Mean Apparent Diffusion Coefficient Value in Patients with Prostate Cancer Treated with Definitive Radiotherapy(2022) Onal, C.; Erbay, G.; Guler, O. C.; Oymak, E.; Yavas, C.; Yavas, G.; 0000-0002-1706-8680; AAK-5370-2021